Skip to main content

Table 1 Demographic and clinical features for all patients

From: A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma

  n %
Gender   
  Male 31 73.8%
  Female 11 26.2%
Age   
  ≤ 50 years 20 47.6%
  > 50 years 22 52.4%
Distance from anal verge   
  ≤ 5 cm 27 64.3%
  > 5 cm 15 35.7%
cT   
  T3 28 66.7%
  T4 14 33.3%
cN   
  N0 5 11.9%
  N1 22 52.4%
  N2 15 35.7%
Total 42 100.0%